Serum Transthyretin as a Prognostic and Therapeutic Biomarker in Transthyretin Amyloid Cardiomyopathy Patients Treated with Tafamidis. [PDF]
J Clin MedCostantino J +7 more
europepmc +1 more source
Neurohormonal Therapy in Patients With Transthyretin Cardiac Amyloidosis: Is it an Option? [PDF]
JACC Case RepEnríquez-Vázquez D +9 more
europepmc +1 more source
Correlation between neuropathy severity and neurofilament light chain levels in Brazilian patients with hereditary transthyretin amyloidosis. [PDF]
Sci RepFerreira P +6 more
europepmc +1 more source
Disease-Modifying Therapies for Hereditary Transthyretin Amyloidosis with Polyneuropathy: Current Status and Future Perspectives. [PDF]
Neurol TherIde T, Yoshikawa M, Koike H.
europepmc +1 more source
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy [PDF]
Journal of Neurology, 2013 Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-month randomized controlled trial (study Fx-005).
Jeffery W. Kelly +2 more
exaly +2 more sources
A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis [PDF]
Neurology and Therapy, 2015 Transthyretin (TTR)-related amyloidosis (ATTR) is a devastating disease which affects a combination of organs including the heart and the peripheral nerves, and which has a fatal outcome if not treated within a average of 10 years.
Márcia Waddington Cruz
exaly +2 more sources
Related searches:
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy
JACC: Heart Failure, 2021Mathew S Maurer, Kurt Boman, John L Berk
exaly